Why Are Moderna Shares Trading Higher Today?
Moderna Inc (NASDAQ; MRNA) shares are trading higher after the company reported a small profit of $0.19 per share,…
Kenvue’s IPO Extravaganza: A Historic $41 Billion Spinoff from Johnson & Johnson
Johnson & Johnson's (NYSE: JNJ) consumer-healthcare business carve-out, Kenvue Inc,
Why Tandem Diabetes Care Shares Are Falling Today
Tandem Diabetes Care Inc (NASDAQ: TNDM) shares are down Thursday morning as its Q1 results missed Street expectations.
Volkswagen Reports Strong Q1 Results On Higher Sales In Europe And North America
Volkswagen AG (NYSE: VWAGY) reported Q1 2023 sales revenue increased 22% Y/Y to €76 billion, led by improved sales volumes in…
American Electric Power Q1 EPS In-Line With Estimates, Guidance Reiterated
American Electric Power Co Inc (NASDAQ:AEP) reported Q1 2023 operating EPS of $1.11, down from $1.22, which came in line…
ConocoPhillips Reports Mixed Q1 Earnings, Average Realized Price Dips
ConocoPhillips (NYSE:COP) reported Q1 2023 adjusted EPS of $2.38, beating the consensus of $2.10. Revenues of $15.5 billion declined from $19.3 billion…
Shell’s Strong Operational Performance Continues In Q1, Plans $4B Share BuyBack Program
Shell Plc (NYSE:SHEL) reported Q1 2023 adjusted EBITDA of $21.4 billion, higher than $19.0 billion a year ago, on…
A Shot of Success: GSK’s Arexvy Wins FDA Approval, Pioneering RSV Prevention for Older Adults in Multi-Billion Dollar Market
The FDA has approved GSK Plc's (NYSE: GSK) Arexvy (respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals
Horton’s Hot Streak: Analysts Savor Tim Horton Parent’s Flavorful Q1 Results, Boosting Price Targets
Several analysts are upbeat on the growth prospects of Restaurant Brands International Inc (NYSE:QSR) and raised the price target. Analysts are…
Insurers Can’t Use War Argument: Court Rules in Favor of Merck in $1.4 Billion Cyberattack Coverage Case
A New Jersey appellate court ruled that a group of insurers can’t use war as an argument to deny Merck & Co Inc (NYSE: MRK) coverage from the $1.4 billion cyberattack that happened in 2017.